





From Stem Cells to IPS Cells.  
A Passionate Journey 
Justo Aznar
There is no doubt that this scientificfinding could have potential clinicaluse, and as such it has been met with
great hope, not only by medical science but
also by the general public.
In addition to the unquestionable scientific
interest in this finding is the fact that obtain-
ing the aforementioned cells, which are sim-
ilar to embryonic cells, does not require the
destruction of human embryos, thus avoid-
ing the serious ethical difficulty that the use
of embryonic stem cells entails; it is well
known that the human embryos from which
they originate must be created and destroyed
to obtain them.
This triple aspect – scientific interest, possi-
ble clinical usefulness and ethical goodness –
has meant that as previously mentioned, the
work by the Japanese and American re-
searchers has been deserving of significant
media attention. 
However, the current study, conducted using
human skin cells, has had its experimental
prologue with animals and even its theoret-
ical formulation stage.
In reality, it all originated when a few years
ago, the dilemma of obtaining cells similar to
embryonic cells by ethically correct proce-
dures, i.e. by mechanisms which do not re-
quire the destruction of human embryos,
was raised, since many researchers consider
that embryonic stem cells constitute valuable
biological material for important fundamen-
tal biomedical research1.  Thus, the search for
alternative sources of stem cells became a
prime research objective.
Before using the reprogramming of adult
human tissue cells to obtain cells similar to
embryonic cells, other avenues were ex-
plored with the same end and are briefly
summarised below.
The first possibility proposed was to obtain
stem cells from embryonic blastomeres gen-
erated by in vitro fertilisation. In fact, if one
cell is extracted from a 4 or 8 cell embryo, it
can be cultured to generate stem cells and
the embryo, even with one cell less, can sur-
vive if implanted in the uterus.
This technique was first used in 2004 by
Strelchenko et al from the Reproductive
Genetics Institute, Chicago, directed by Y
Verlinsky2; they managed to obtain various
cell lines from one pluripotent cell extracted
from a 4-day old embryo (of 60 to 70 cells)
generated by in vitro fertilisation, i.e. imme-
diately before it reached the blastocyst devel-
opmental stage, which as mentioned, is
achieved when the embryo is approximately
five days old. When this technique is used,
most of the time extraction of the cell to be
used to generate the stem cells does not re-
sult in death of the embryo. However, to
ethically legitimise this technique, it would
have to be guaranteed that the embryo from
which the blastomere used to generate the
stem cells was extracted was subsequently
implanted to prevent its destruction, some-
thing which in our opinion is difficult to en-
sure.
A step forward in the same direction was
subsequently taken when Chung and a



























company ACT (Advanced Cell Technology),
led by Robert Lanza, undoubtedly one of
the pioneers in this type of research, man-
aged to obtain different tissue cell lines, such
as bone, cartilage, neural tissue and respira-
tory epithelial cells, from embryo blas-
tomeres of only eight cells3. 
Nevertheless, even then these experiments
gave rise to undeniable therapeutic expecta-
tions, it did not appear that the cells thus ob-
tained could be used for therapeutic pur-
poses as they came from an individual other
than the person requiring the cell transplant,
which could lead to immunological rejec-
tion problems, similar to that which occurs
with donor organ transplants.
The second attempt was to propose the cre-
ation of pseudo-embryonic biological struc-
tures generated by a technique called altered
nuclear transfer (ANT), suggested recently
by William B Hurl but4 of Stanford Univer-
sity in California.This author proposed ge-
netic modification of the transferred somatic
nucleus so that a human embryo could never
develop from the biological entity generated,
although cell lines similar to embryonic stem
cells, and therefore useful for biomedical ex-
periments, could be obtained; however, in
the opinion of DA Melton from the Harvard
Stem Cell Institute5, this option had funda-
mental errors which somehow devalued the
results obtained with it.
According to Hurlbut, ANT is carried out in
three steps6.  In the first, a somatic cell is
taken from an adult subject and the chro-
matin structure of its nucleus is modified so
that when this modified nucleus is trans-
ferred to the enucleated oocyte, it can never
result in an embryo which is capable of de-
veloping normally. Subsequently, the
pseudo-embryo thus generated is appropri-
ately stimulated so that it can develop to give
rise to a pseudo-blastocyst, which is theoret-
ically incapable of generating a normal em-
bryo, but from which cells similar to human
embryonic stem cells can be extracted; hy-
pothetically, these could be used for bio-
medical research.
As a tangible demonstration of the creative
capacity of those who research in the bio-
medical field, Hurlbut’s theoretical proposal
was almost immediately put into practice by
Meissner and Jaenisch7; the
latter is known to be one of
the most qualified experts in
stem cell cloning and exper-
imental techniques. These
authors were able to create
pseudo-embryos from a type
of adult somatic cell, fibrob-
lasts, the genomic material
of which was modified so
that it could not express
Cdx2, a gene necessary for
the proper development of
the trophoblast, which is known to be essen-
tial for embryo implantation8 Thus, the
pseudo-embryos generated by this technique
would be non-viable, as they would be un-
able to implant in the uterus, although they
could constitute a source of stem cells similar
to human pluripotential embryonic stem
cells9.
However, from a bioethical point of view,
this technique has objective difficulties since,
although an altered blastocyst incapable of
implanting in the uterus can be produced, it
is not possible to rule out that the embryonic
entity thus generated, at some stage in its de-
velopment, has not had the characteristics of
a viable human embryo10, a fact which is ex-
perimentally difficult to verify at present. 
Furthermore, it seems obvious that although
these embryos may not be viable due to
their altered genetic nature, they nevertheless
continue to be human beings in the embry-
onic phase which have been unnaturally
manipulated. Moreover, the fact of produc-
ing an embryo which is incapable of surviv-
ing would be tantamount to the creation of
defective human lives, something which is
difficult to justify ethically.
The third possibility was the creation of
pseudo-embryonic biological structures for
altered nuclear transfer with oocyte assisted
reprogramming (ANT-OAR).
This technique attempted to reprogram stem
cells from adult tissues to convert them into
pluripotent stem cells, from which cells of all
tissue types could be obtained, but without
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Many ways have being
explored: extracting
some cells form the em-
bryo without destroing
it; Altered Nucear Tran-
sfer; Oocite Assisted Re-
programming; the fu-
sion of genetically modi-
fied somatic cells with
embryonic stem cells…
the reprogramming ever converting them to
totipotent stem cells from which a complete
human embryo could develop.
When somatic nuclear transfer is used to
generate clone embryos, the enucleated
oocyte cytoplasm has the ability to repro-
gram the genome of the adult cell. To that
end, in ANT-OAR, the genetically modified
nucleus of the adult cell is activated by fac-
tors in the cytoplasm of the oocyte to which
it is transferred.From this, a biological entity
is formed from which pluripotent cells
which can be used for biomedical experi-
ments can be obtained, but which will never
generate an embryo.
This technique, from an ethical point of view
does not appear to offer objective difficulties
and so has been endorsed by a significant
number of prestigious scientists and bioethi-
cists in a document entitled Production of
Pluripotent Stem Cell by Oocyte Assisted
Reprogramming http://www.eppc.org/
publications/pubID.2374/pub_detail.asp).
However, there is serious difficulty in the
fact that human oocytes are required to
carry out the procedure, which means using
a large number of oocyte donors, something
which is not easy to achieve, particularly
due to the risk posed to each of these
women by the significant hormone stimula-
tion which they undergo and which occa-
sionally may result in severe ovarian hyper-
stimulation syndrome.
The fourth possibility is the creation of
pseudo-embryonic biological structures by
fusion of the genetically modified adult so-
matic cells with embryonic stem cells.
To resolve the serious problem of the use of
human oocytes that ANT-OAR entails, it
was proposed to fuse the nucleus of the ge-
netically modified adult somatic cells with
embryonic stem cells instead of doing so
with oocytes, since the embryonic stem cells
produce the same reprogramming effect in
the genome of the adult somatic cell as the
cytoplasm of the oocytes in somatic nuclear
transfer.According to M Azim Surani11, it is
even possible that the embryonic stem cells
are more efficient at reprogramming the
chromosome material of the adult somatic
cells than the cytoplasm of the oocytes itself.
In this way, the resulting adult somatic cells,
called cybrids by some12, may attain a state of
genomic undifferentiation similar to that of
pluripotent cells, to thus be able to derive
stem cells similar to embryonic stem cells
from them.
This hypothetical possibility, which had al-
ready been proposed by M Tada et al13 was
put into practice by Cowan et al14, who
showed that if somatic cells are fused with
embryonic stem cells, reprogramming of the
chromosome material of the adult cells
could be achieved up to the stage of pluripo-
tent undifferentiated cells.
However, according to an editorial by E
Phimister in the New England Journal of
Medicine15, despite this encouraging possi-
bility, Kevin Eggan, one of the members of
Cowan’s own group and also co-author of
the abovementioned paper, showed that it
had still not been possible to fine tune the
methodology necessary to generate stem
cells similar to those obtained from blasto-
cysts, although their studies may be the basis
for future experiments which would allow
this objective to be met.
In fact, the main biological disadvantage of
this technique is that as the new cell derives
from two cells, fibroblast and embryonic
stem cell, which have a diploid nucleus (46
chromosome nucleus), the resulting cell will
have double the chromosome content of
normal adult cells, i.e. it will be a tetraploid
cell with 92 chromosomes. Although the
behaviour of tetraploid cells thus obtained is
very similar to that of embryonic stem cells,
they have practically no therapeutic potential
and so can only be used for biomedical ex-
perimental objectives but never for thera-
peutic purposes. Consequently, as the au-
thors themselves state16, and also mentioned
in a JAMA editorial17, in order to make
these techniques therapeutically useful, a
method would have to be developed to re-
move the excess DNA contributed by the
embryonic stem cell, to thus convert the
tetraploid cell obtained into diploid, some-
thing which as Eggan himself recognises,
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seems to be technically difficult to achieve at
present.
From an ethical point of view, there is one
problem, in my opinion insurmountable, in
that in order to obtain this type of tetraploid
cell, embryonic stem cells must be used;
these are obtained from human embryos
which have to be destroyed and therefore
this technique would not resolve the ethical
difficulty that the use of embryonic stem
cells entails, since obtaining them requires
ending the life of the donor embryo.
The fifth possibility is obtaining them from
pseudo-embryos. As is known, normal zy-
gotes have two pro-nuclei, one from the fa-
ther and the other from the mother. How-
ever, after in vitro fertilisation, zygotes
containing one or three pronuclei can be ac-
cidentally obtained; these zygotes are called
aneuploids and are generally non-viable. It
has been shown that normal embryonic
stem cells which may be used for biomedical
research can be obtained from the blastocyts
of aneuploid embryos18. 
However, positive ethical evaluation of this
technique must be made prudently, as it has
been previously shown19y20 that between
10% and 30% of aneuploid zygotes obtained
by in vitro fertilisation produce viable blas-
tocysts which may give rise to normal em-
bryos.The consequences that the hypothet-
ical transplants carried out with a type of
cells which have an unbalanced genetic load
may have for the recipient cannot be pre-
dicted either.
The sixth possibility is to obtain stem cells
similar to embryonic stem cells from testic-
ular stem cells which are pluripotent and
which can behave as embryonic stem cells.
This has been achieved by Guan et al21 on
confirming the pluripotentiality and plastic-
ity of the immature masculine germ cells of
adult mice; they found that using proper
culture conditions, they could acquire bio-
logical properties similar to those of embry-
onic stem cells. The authors of the paper
called these cells “multipotent adult germline
stem cells” or maGSCs.
Stem cells similar to embryonic stem cells are
obtained from maGSC cells from which
nerve, heart, liver or intestinal cells can be
derived.
However, at present, this technique can only
be applied for therapeutic purposes to males,
which means a significant limitation that
will undoubtedly have to be resolved in the
near future.
Expanding on the experiments by Guan et
al, M Seandel et al22 showed that spermato-
gonia progenitor cells (SPCs) can be ob-
tained from testicular stroma;  multipotent
adult stem cells (MACs) can be derived from
the SPCs and then the MACs are used to
develop contractile cardiac cells “in vitro”,
like functional blood vessels “in vivo”. Thus,
the authors believe that MACs may be used
for genetic studies, to promote tissue regen-
eration and for the recovery of ischaemic or-
gans.This is unquestionably a great and en-
couraging scientific advance.
The seventh possibility is to obtain stem
cells similar to embryonic stem cells from
unactivated oocytes (unfertilised or unactive
by somatic nuclear transfer).These oocytes
cannot give rise to a viable embryo, so in
principle, their cells could be used without
any ethical problems to generate cell lines
similar to human embryonic cell lines.
In this respect, some time ago two attempts
were made to obtain human cell lines similar
to embryonic cell lines from parthenotes
(parthogenetically activated ova), one by JB
Cibelli’s team23 and the other by H Lin’s
group 24, but without achieving specific re-
sults. Now, it appears that a team of Russian
and American researchers have managed it25.
In fact, Revazova’s group have obtained
pluripotent cell lines from parthenogeneti-
cally generated blastocysts. The cells thus
produced have morphology similar to hu-
man embryonic stem cells, express specific
markers of these cells, have a high level of al-
kaline phosphatase and telomerases and ex-
press a normal 46 chromosome karyotype. In
other words, they are cells which are similar
to human embryonic stem cells, which can
be used to generate different tissue cells and
which may potentially be used for therapeu-
tic purposes.These cells have been able to be
cultured over 21 to 35 passes. However, the
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use of these cells has several limitations. First,
is that to obtain them requires the use of a
large number of human oocytes, which as
previously mentioned, has unquestionable
ethical objections, as it is not easy acceptable
for women to be used as a source of oocytes.
Second, and contrary to the procedure pro-
posed by Guan et al26 which could only be
applied to males, is that the cells obtained
could only be used to treat the women who
donate their ova. In this case, as this is an au-
tologous transplant, immunological rejection
is avoided, as has been already demonstrated
in mice27.
In any case, Revazova et al28 are convinced
that they have developed a method to “pa-
thenogenetically create human embryonic
stem cells and of having shown that these
cells can differentiate into functional cells
which may be of great value in the future to
treat human degenerative diseases as well as
for biomedical research”.
Along the same line as
Revazova et al, a group
of researchers from the
University of Milan state
that they have produced
embryonic stem cells pa-
thenogenetically, although their results have
still not been published, as mentioned in
Nature29.
In any case, it is worth considering that al-
though it is generally stated that parthenotes
are not viable, there are species of American
lizards, genus Cnemidophorus, from the
family Teiidal, which naturally reproduce
parthenogenetically, generating colonies of
perfectly viable females. Therefore, in our
opinion, it cannot be completely excluded
that human parthenotes could not in some
measure be equally viable.
The last possibility of which we are aware
obtained cells similar to embryonic stem
cells by direct reprogramming of adult so-
matic cells, proposed by K Takahashi and S
Yamanaka30. This Japanese team analysed
which factors present in human oocytes or
in embryonic stem cells induced reprogram-
ming of adult somatic cells, and identified
several of them, using four:Oct3/4, Sox2, c-
Myc and Klf4.  These four genes code four
specific proteins, known as transcription fac-
tors, which are those which are transferred
to the somatic cell. These proteins induce the
expression of other genes which reprogram
the somatic cells to a state of pluripotential-
ity. Using these four genes, they managed to
reprogram mouse adult somatic cells which
express the pluripotentiality marker Fbx15,
from which cells of all tissue types can be di-
rectly obtained without having to destroy
any embryos.  This is because at no time in
the induced reprogramming are true embry-
onic cells generated, as the reprogramming
process is always stopped in the evolutionary
stage of the pluripotent cell.These cells were
called induced pluripotent stem cells or iPS
cells.However, the iPS cells generated differ
from embryonic stem cells in their gene ex-
pression and in the DNA methylation pat-
terns.When the iPS cells thus formed are in-
jected into the blastocysts of normal animals,
they do not produce viable chimeras.
These results were expanded and confirmed
in a subsequent study by the same group31,
in which they managed to generate
germline-competent iPS cells with genetic
expression and DNA methylation patterns
comparable to those of embryonic stem cells
from iPS cells by controlling the expression
of Nanog and Oct3/4. Likewise, they man-
aged to obtain mouse adult chimeras which
can transmit their genetic characteristics to
the following generation if they injected
them in murine blastocysts.  However, ap-
proximately 20% of the mice generated de-
veloped tumours, possibly due to the use of
c-Myc, which as previously mentioned is an
oncogene.R Jaenisch also showed that some
chimeras generated with iPS cells developed
tumours 32.
In other words, the iPS cells obtained from
the murine fibroblasts may generate
chimeras with the ability to transmit their
gene characteristics to the following gener-
ation.
In the same edition of Nature33, Wer nig et al,
from the Jaenisch group, also achieved the in
vitro reprogramming of fibroblasts to
pluripotent cells, using the same reprogram-
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The last possibility is by
direct reprogramming
of adult somatic cells
ming genes, Oct4 (also called Oct3/4 or
Pou 5f1), Sox2, c-Myc and Klf4, verifying
that the DNA methylation pattern, gene
expression and the chromatin state of the
pluripotent cells generated are similar to
those of embryonic stem cells. Likewise, they
managed to form chimeras, from which live
term embryos developed, if injected in
murine blastocysts.
Similarly, Maherali et al34 and Daley et
al35have managed to reprogram fibroblasts
into induced pluripotent cells (iPS) and are
the first to generate viable chimeras.
Everything up to this point has been carried
out prior to the publication of the recent ex-
periments of the US and Japanese groups
which have been the reason for this review.
However, the step which must be taken to
transfer these experiments to humans does
not appear to be easy or close at hand.Thus,
asked Janet Rossant last July in Nature36:
“Would the same magic molecular factors
be efficient in generating iPS cells in hu-
mans?Various groups are trying to do so, but
transferring these tests to humans has many
difficulties”.
In fact, the great advance which has now
been achieved by Shinya Yamanaka’s group
from Kyoto University and James Thomson’s
group from the University of Wisconsin, is
that the previously mentioned experiments
by Takahashi and Yamanaka, conducted with
murine fibroblasts37, have now been carried
out using human skin cells as the cell mate-
rial to be reprogrammed.Thus, in view of its
possible clinical use, a fundamental step for-
ward has been taken, and so interest has
been aroused in the experiments that we are
discussing.
Thomson’s team have published their exper-
iments in Science38; as is well-known, Thom-
son was the researcher who in 199839 first
managed to culture human embryonic cells.
In order to achieve reprogramming of skin
cells, these authors used a lentivirus as a vec-
tor to introduce the 4 genes which are used
to reprogram the fibroblasts.The reprogram-
ming genes used were Oct3/4, Sox2, Lin28
and Nanog.
For this procedure, the US researchers ob-
tained 8 iPS cell lines, similar to the embry-
onic cell lines, allowing some of them to cul-
ture for 22 weeks. Finally, they managed to
generate one iPS cell from every 10,000 re-
programmed somatic cells. The sources of
the skin cells used were the foreskin of a
newborn and the skin of a foetus.
Takahasi and Yamanaka used the same system
as the Americans40, but using a retrovirus to
transfer the reprogramming genes; further-
more, these were not the same as those used
by Thomson, since they used Oct3/4, Sox2,
c-Myc and Klf4.  These were the same as
they had already used in their previous ex-
periments with mice41, aided in this case
with a protein receptor SLc7a1, to improve
the efficiency of the technique.Using this ex-
perimental method, they obtained one iPS
cell per 5000 reprogrammed
somatic cells, i.e. they man-
aged to double the efficiency
of Thom son’s team. This
means that ten centimetres of
cultured skin could produce
several iPS cell lines. 
However, the use of c-Myc,
an oncogene, by Takahashi
and Yamanaka added a seri-
ous difficulty to their method
in order for the cells obtained
from the iPS to be used in
human clinical treatment, since in this case it
could favour tumour development in the
hypothetical transplanted patients. Never-
theless, in a subsequent study42, the same
group achieved similar effects, both in hu-
mans (using skin cells from a 36-year old
adult) and in mice when c-Myc was not
used, i.e. using only the other three repro-
gramming genes, with the result that none of
the 26 animals to which iPS cells obtained
without using c-Myc developed tumours,
while 6 of 37 animals transferred with cells
which used c-Myc produced them.
In the Japanese experiments, skin from the
face of a 36-year old woman and joint syn-
ovial tissue from a 69-year old male were
used as a source of adult cells.
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The iPS cells showed
characteristics of em-
bryonic cells, both in
morphological appea-
rance and in their mul-
tiplication in culture,
similar functionality
and ability to produce
teratomas.
92
The iPS cells obtained by the Yamanaka
group showed characteristics of embryonic
cells, both in morphological appearance and
in their multiplication in culture, similar
functionality, ability to produce teratomas,
and particularly the same genetic markers, al-
though the genetic expression of the iPS
cells and the DNA methylation patterns
were different and especially failed in the
production of live chimeras.
From the iPS cells thus obtained, they were
able to achieve biological structures with
the three germinal layers, from which all
the cells in our body are derived, but in ad-
dition, when cultivated properly, they also
managed to generate neuron and cardiac
cells, with the peculiarity that the latter be-
gan to beat after a few days culture.
Undoubtedly, the main advantage of the use
of iPS cells is ethical, as it does not require
the destruction of human
embryos to obtain them.
This has been recognised
by a large number of
bioethics experts, as well
as by researchers who
work in this passionate
area.
However, they also have
unquestionable biologi-
cal advantages with re-
spect to embryonic stem cells, if the aim of
their use is therapeutic. In fact, if stem cells
from embryos left over from in vitro fertil-
isation are used, as the embryo used is a hu-
man individual who is different from the
person intended to benefit from the trans-
plant, there is a high probability of inducing
immunological rejection.As is obvious, this
presents serious difficulty for the use of
embryonic stem cells for therapeutic ends.
This would be resolved with iPS cells, be-
cause as they come from the same individ-
ual requiring the cell transplant, rejection
would not occur. However, it is still early to
be optimistic when it comes to searching
for a therapeutic goal, since the disadvan-
tages to be overcome before being able to
use iPS cells in humans for clinical purposes
are now objectives.
The first of these is that in order to insert the
four (or even only three) reprogramming
regulatory genes (genes which produce pro-
teins which in turn control the activity of
other genes) viruses were used, retroviruses
in the case of Tak ahashi and Yamanaka and
lentiviruses in the case of Thomson.  The ge-
netic material of these viruses, which are po-
tentially pathogenic, may insert itself in the
DNA of the cell to be reprogrammed, and
so could transmit viral diseases to the hypo-
thetical recipient. In any case, this difficulty
could be overcome using the homologous
recombination presently used to produce
“knocked-out” animals; as is well-known,
these are normal except in the gene which
has been specifically removed or inactivated.
In other words, in this way, the four repro-
gramming genes can be inserted in a di-
rected and innocuous manner, transfecting
the fibroblasts with suitable constructions
using electroporation.
The second difficulty is that since the iPS
cells are very undifferentiated, although less
so than the embryonic cells, like these they
have the possibility of developing tumours in
the potential recipients, although to a lesser
degree as they are not as undifferentiated.
An additional difficulty may also be the in-
tense genetic modification involved in the
introduction of the four regulatory tran-
scription genes, the genetic consequences of
which are presently unpredictable.
In any case, a final comment seems appropri-
ate. Until the aforementioned difficulties
have been resolved to be able to use iPS cells
for therapeutic ends in humans, these cells
may be biological material of great interest
for experimental objectives, those which
they are now attempting to achieve using
embryonic stem cells, without their use en-
tailing any ethical difficulty.Thus, using iPS
cells, it will be possible to continue research-
ing the biological regulation of the first
stages of human life, learning more about the
pathogenic mechanism of many diseases and
using them as a biological means to evaluate
new drugs. However, surely one of the first
practical applications of iPS cells could be
the possibility of obtaining cell models of
Until the difficulties
have been resolved to be
able to use iPS cells for
therapeutic ends in hu-
mans, these cells may be
biological material of
great interest for experi-
mental objectives
human genetic diseases, deriving cell lines
from patients who suffer them. In this way
it would be possible to both deepen the un-
derstanding of their pathogenicity and to
advance their treatment.
Outside these biomedical considerations, it
seems interesting to consider that the pro-
duction of iPS cells is technically more sim-
ple and consequently more economical that
somatic nuclear transfer, so in theory, these
procedures could be carried out in laborato-
ries which do not have large technical re-
sources.
Finally, it is worth noting that the impor-
tance of these findings may be inferred from
the fact that several of the pioneers in the use
of embryonic stem cells have shown their in-
tention to stop using them to redirect their
research with iPS cells.Among them, Ro bert
Lanza, director of Advanced CellTechnology,
one of the leading companies in experi-
mentation with human embryos and Ian
Wilmut, the “father” of Dolly the sheep,
who after declaring that the research that
may result from the use of iPS cells is “a hun-
dred times more interesting” than that con-
ducted with embryonic stem cells, have
shown their intention to stop using embry-
onic stem cells in favour of using iPS cells43.
This is undoubtedly a great experimental
advance, which must be greeted as a great
hope for finding ethical pathways which al-
low the development that reparatory and
regenerative medicine requires.To that end,
Thomson himself commented44 that proba-
bly “a decade from now, stem cell wars will
be just a funny historical footnote on a page
in the history of science”.
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